Product Images Eluryng
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 15 images provide visual information about the product associated with Eluryng NDC 65162-469 by Amneal Pharmaceuticals Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1 - eluryng 1
Not available.*
FIGURE J - eluryng 10
Pouch label - eluryng 11
Carton label - eluryng 12
Peel off - eluryng 13
EluRyng is a vaginal ring contraceptive that delivers a daily dose of 0.120 mg/0.015 mg of etonogestrel and ethinyl estradiol. Each ring contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol, and can be used for up to 3 weeks. The product is intended to prevent pregnancy and is not effective against sexually transmitted infections. EluRyng should be stored in a refrigerator before dispensing to the patient and can be stored at room temperature (20 to 25°C) for up to 4 months after dispensing. The dispenser should apply an expiration date label that does not exceed four months from the date of dispensing over the preexisting expiration date on each pouch.*
pharma label - eluryng 14
Useful description: These are stickers for your calendar to help remember the insertion and removal times for the etonogestrel/ethinyl estradiol vaginal ring.*
eluryng 15
This text contains instructions for dispensers regarding the etonogestrel/ethinyl estradiol vaginal ring. The dispenser must place an adhesive label on the pouch containing the ring with the expiration date, which should not exceed 4 months from the date of dispensing or the preprinted expiration date. The label should be applied over the preexisting expiration date on each pouch and the outer carton when all three pouches are dispensed. There is also a label to reseal the carton, and it appears that there are multiple places where the expiration date should be listed.*
formula - eluryng 2
This document lists various studies that evaluate the risk of breast cancer associated with combined oral contraceptives. The studies are categorized into two comparisons: ever COC use vs. never COC use and current COC use vs. never use. The studies listed are from different countries and present different effect estimates, such as odds ratios (OR), relative risks (RR), and hazard ratios (HR). However, some of the text seems to depict a graph or table that is not fully recognized by the technology.*
Figure 2 - eluryng 3
PIC 1 - eluryng 4
PIC 2 - eluryng 5
FIGURE ABC - eluryng 6
FIGURE DE - eluryng 7
Figure F - eluryng 8
FIGURE GHI - eluryng 9
The text describes medical terms related to female reproductive organs and the use of a vaginal ring containing the hormones etonogestrel and ethinyl estradiol.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.